During the past decade, ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 13 clinical trials were completed, i.e. on average, 37.1% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 5 clinical trials were completed. i.e. 45.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 31 trials, followed by "Hoffmann-La Roche" with 13 trials sponsored, "Fondazione Italiana Linfomi ONLUS" with 6 trials sponsored, "Gruppo Italiano Trapianto di Midollo Osseo" with 5 trials sponsored and "Heart Care Foundation" with 5 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO" #1 collaborator was "Agenzia Italiana del Farmaco" with 2 trials as a collaborator, "Azienda Sanitaria-Universitaria Integrata di Udine" with 2 trials as a collaborator, "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 2 trials as a collaborator, "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 2 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO" are "Chronic Myeloid Leukemia" (6 trials), "Leukemia" (6 trials), "Multiple Sclerosis" (4 trials), "Acute Lymphoblastic Leukemia" (3 trials) and "Chronic Lymphocytic Leukemia" (3 trials). Many other conditions were trialed in "ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO" in a lesser frequency.

Most popular intervention types in "ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO" are "Drug" (53 trials), "Other" (20 trials), "Procedure" (4 trials), "Biological" (2 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (6 trials), "Placebo" (5 trials), "Obinutuzumab" (3 trials), "idarubicin" (3 trials) and "Bendamustine" (2 trials). Other intervention names were less common.

The vast majority of trials in "ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO" are 79 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO". undefined are not yet recruiting, 11 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 44 completed trials in ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO, 1 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".